FIELD: medicine.
SUBSTANCE: invention relates to medicine and relates to method for determining functional fibrinogen comprising the examination of a whole blood sample by thromboelastography. Heparinized blood and batroksobin are introduced into a cuvette for thromboelastography, followed by thromboelastography, determining the maximum amplitude parameter (MABatrox) on a thromboelastogram, and the concentration of functional fibrinogen (FFBatrox) is calculated by the formula: FFBatrox = 0.1153 × MABatrox + 0.5903, where FFBatrox – concentration of functional fibrinogen (g/l), MABatrox – maximum amplitude on thromboelastogram with heparinized blood and batroksobin (mm), 0.1153 and 0.5903 – conversion factors.
EFFECT: invention provides increase in accuracy of determining the concentration of functional fibrinogen at the maximum amplitude of thromboelastogram of heparinized blood, in which the formation of a fibrin clot is induced by the addition of batroxobin.
1 cl, 4 ex, 10 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR DETERMINING FIBRINOGEN DURING RECALCIFICATION OF CITRATE PLASMA AND EVALUATING ITS FUNCTIONALITY | 2019 |
|
RU2703541C1 |
| METHOD FOR DETECTING HEPARIN IN BLOOD | 2017 |
|
RU2662171C1 |
| METHOD FOR DETERMINING FIBRINOGEN AND EVALUATING ITS FUNCTIONALITY | 2019 |
|
RU2712643C1 |
| METHOD FOR ASSESSING HEMOSTATIC ACTIVITY | 2015 |
|
RU2601111C1 |
| METHOD FOR DETERMINING FIBRINOGEN AND FUNCTIONALITY EVALUATION THEREOF | 2020 |
|
RU2732388C1 |
| METHOD OF ESTIMATING CONDITION OF BLOOD COAGULATION SYSTEM IN PATIENTS IN CRITICAL CONDITION | 2012 |
|
RU2517116C2 |
| METHOD OF DETERMINING ACTIVITY OF ANTITHROMBINE III IN BLOOD PLASMA | 0 |
|
SU1522102A1 |
| METHOD FOR DETECTING BLOOD CLOTTING FACTOR DEFICIENCY BY THROMBOELASTOMETRY | 2019 |
|
RU2699798C1 |
| METHOD OF DETERMINING DISTURBED ACTIVITY OF BLOOD PLASMA FIBRINOGEN | 0 |
|
SU1458824A1 |
| METHOD FOR PREDICTION OF BLEEDING IN NEWBORNS WITH VERY LOW OR EXTREMELY LOW BODY WEIGHT | 2016 |
|
RU2623868C1 |
